J Periselneris1, L Nwankwo2, S Schelenz3, A Shah1, D Armstrong-James4. 1. Department of Respiratory Medicine, Royal Brompton & Harefield NHS Foundation Trust, London, UK. 2. Department of Pharmacy, Royal Brompton & Harefield NHS Foundation Trust, London, UK. 3. Department of Microbiology, Royal Brompton & Harefield NHS Foundation Trust, London, UK. 4. National Heart & Lung Institute, Imperial College London, London, UK.
Abstract
OBJECTIVES: Allergic bronchopulmonary aspergillosis (ABPA) can accelerate lung function decline in patients with cystic fibrosis (CF). Antifungal medication can be used in addition to systemic corticosteroid treatment. PATIENTS AND METHODS: We evaluated Aspergillus-specific IgE and the use of therapeutic drug monitoring of triazoles in a retrospective analysis of 32 patients. RESULTS: There was a significant reduction in Aspergillus IgE with posaconazole but not with other triazoles (P = 0.026). Aspergillus IgE levels were inversely correlated with the therapeutic drug level of posaconazole. CONCLUSIONS: These data suggest that posaconazole is better than comparator azoles at decreasing serological response to Aspergillus and that this response was better with therapeutic levels of posaconazole.
OBJECTIVES:Allergic bronchopulmonary aspergillosis (ABPA) can accelerate lung function decline in patients with cystic fibrosis (CF). Antifungal medication can be used in addition to systemic corticosteroid treatment. PATIENTS AND METHODS: We evaluated Aspergillus-specific IgE and the use of therapeutic drug monitoring of triazoles in a retrospective analysis of 32 patients. RESULTS: There was a significant reduction in Aspergillus IgE with posaconazole but not with other triazoles (P = 0.026). Aspergillus IgE levels were inversely correlated with the therapeutic drug level of posaconazole. CONCLUSIONS: These data suggest that posaconazole is better than comparator azoles at decreasing serological response to Aspergillus and that this response was better with therapeutic levels of posaconazole.
Authors: Thomas J Walsh; Issam Raad; Thomas F Patterson; Pranatharthi Chandrasekar; Gerald R Donowitz; Richard Graybill; Reginald E Greene; Ray Hachem; Susan Hadley; Raoul Herbrecht; Amelia Langston; Arnold Louie; Patricia Ribaud; Brahm H Segal; David A Stevens; Jo-Anne H van Burik; Charles S White; Gavin Corcoran; Jagadish Gogate; Gopal Krishna; Lisa Pedicone; Catherine Hardalo; John R Perfect Journal: Clin Infect Dis Date: 2006-11-28 Impact factor: 9.079
Authors: Richard Kraemer; Natascha Deloséa; Pietro Ballinari; Sabina Gallati; Reto Crameri Journal: Am J Respir Crit Care Med Date: 2006-09-07 Impact factor: 21.405
Authors: K F Woolnough; M Richardson; C Newby; M Craner; M Bourne; W Monteiro; S Siddiqui; P Bradding; C H Pashley; A J Wardlaw Journal: Clin Exp Allergy Date: 2016-12-02 Impact factor: 5.018
Authors: David A Stevens; Richard B Moss; Viswanath P Kurup; Alan P Knutsen; Paul Greenberger; Marc A Judson; David W Denning; Reto Crameri; Alan S Brody; Michael Light; Marianne Skov; William Maish; Gianni Mastella Journal: Clin Infect Dis Date: 2003-10-01 Impact factor: 9.079
Authors: Neha Agarwal; Louise Apperley; Norman F Taylor; David R Taylor; Lea Ghataore; Ellen Rumsby; Catherine Treslove; Richard Holt; Rebecca Thursfield; Senthil Senniappan Journal: Case Rep Med Date: 2020-08-28
Authors: Lu Chen; Elke H J Krekels; Paul E Verweij; Jochem B Buil; Catherijne A J Knibbe; Roger J M Brüggemann Journal: Drugs Date: 2020-05 Impact factor: 9.546